MEDICEXUM

The complianceadvantagein cannabis.

Medicexum is the regulatory and commercial partner for suppliers, importers and clinics building inside the UK's most scrutinised emerging market.

Send an email enquiryExplore our services

CBD. Not a controlled drug. In food and supplements it is regulated as a novel food. Same formula as THC: C21H30O2.

1,701,064

Rx items 2025

up 154%

NHSBSA FOI-03941, 30 July 2026

30,061kg

Imports 2025

up 100%

Prohibition Partners, 24 June 2026

60k to 75k

Active patients

Cannabis Industry Council, 15 May 2026

818

Products listed

up 119%

Prohibition Partners, 24 June 2026

Which licences does your operation actually need?

Four questions. An indicative regulatory stack in under a minute.

Question 1 of 4

What are you moving?

Five gates between a grow room and a UK patient.

Every one has its own regulator, licence and paperwork. We get you through each of them, in order.

1

Made to EU GMP

Cultivation and manufacture audited against the standard UK importers have to prove.

2

Home Office licence

Controlled drug licensing and an import licence for each consignment.

3

MHRA licensed importer

Wholesale dealer obligations, GDP, and a Responsible Person framework that holds up at inspection.

4

Specialist pharmacy

Supply agreements with the pharmacies that dispense unlicensed cannabis medicines.

5

Prescribed to a patient

Clinic partnerships and a product specification prescribers will choose.

Cultivators: list your products where only vetted buyers can see them.

CBPM Supply Partners is our UK market access route for licensed cultivators and extract suppliers. Once you are approved, your products, test results and stock go into a locked catalogue. Only vetted trade members can sign in, and nothing is shown to the public.

  • Trade members only, each one vetted
  • Certificates of analysis with the listings
  • Dated stock editions
Apply to list your productsSee how the route works

Trade only. Not consumer advertising and not an offer for sale. Medicexum does not procure, supply or broker cannabis based medicinal products.

The UK is the fastest growing regulated cannabis market in Europe.

Prescription volumes have grown more than tenfold since 2019 and imports doubled last year. Supply is concentrated in a handful of pharmacies, and the ACMD review is pending. Operators that treat compliance as competitive advantage will own the decade.

1,701,064

Items of privately prescribed unlicensed cannabis dispensed in English community pharmacies, 2025.

up 154% on 2024

NHSBSA FOI-03941, released 30 July 2026. Calendar years, England, community pharmacy dispensing.

Privately prescribed unlicensed Schedule 2 CBPM items

2022/232023/242024/25833,525

Source: CQC, The safer management of controlled drugs, annual updates to 10 July 2026. England and Wales, financial years. Growth of 130% then 134%. This is a different basis to the headline NHSBSA figure, so the two series are not comparable.

Imports doubled in a year

20242025

14,992kg in 2024 to 30,061kg in 2025.

Source: Prohibition Partners, UK Medical Cannabis Market Update, 24 June 2026. Canada supplied approximately 57%.

98%

Of CBPM supplied in England came from 10 of the 25 registered pharmacies

Source: GPhC, October 2025.

3

UK marketing authorisations

818

CBPM products available

Almost everything prescribed in the UK is an unlicensed special.

Source: MHRA via Chambers, 28 May 2026, and Prohibition Partners, 24 June 2026.

A complete operating partner for cannabis based medicinal products.

All services

Regulatory compliance

MHRA, GDP and Home Office navigation. Audits, SOPs and Responsible Person frameworks.

Import and export

EU GMP compliant sourcing and licensed importation routes into the UK supply chain.

CBD and novel foods

FSA Novel Foods dossiers, public list status, labelling and reformulation for UK CBD brands.

Supply chain set up

Licence applications, storage, wholesale dealer obligations, stood up end to end.

B2B partnerships

Producers, importers and clinics matched into commercial relationships that scale.

Fixed price from £5,000

Compliance tools

Fixed scope web apps that replace compliance spreadsheets. Supplier approval, CAPA, training, batch release and product registers.

Commercial strategy

Pricing, positioning, go to market plans for new entrants and operators ready to scale.

We don't just advise on compliance systems. We build them.

Four live platforms, built-in house.

Jorja Medical Cannabis
Jorja Medical Cannabis homepage

Jorja Medical Cannabis

Clinic website and patient membership platform for a UK medical cannabis clinic.

Visit site
CBD Compliance Checker
CBD Compliance Checker homepage

CBD Compliance Checker

Free

Free novel food status check against the FSA public list.

Open tool
ClaimSafe
ClaimSafe homepage

ClaimSafe

Claim screening for UK and EU supplement brands.

Visit site
Prescription Portal
Prescription Portal homepage

Prescription Portal

Prescription writing, release and pharmacy workflow for a medical cannabis clinic. Staff access only.

Private system

Want one built for your team?

One workflow turned into a web app, or your idea turned into a working product. Fixed price from £5,000, in about 4 weeks.

See how a build worksBook a scoping call

25 years of pharmaceutical quality, applied to cannabis.

Wilson's career was built in pharmaceutical quality and validation, across GSK, Sanofi, AstraZeneca, Fujifilm Diosynth and Novartis, including commissioning, qualification and remediation programmes run to MHRA and FDA expectations. That is where the standard comes from.

He went on to lead quality and operations for a team of more than 200, and held a Global Head of Quality role inside a FTSE 100 business. Medicexum applies that standard to a market where most operators are still learning it as they go.

  • GSK
  • Sanofi
  • AstraZeneca
  • Fujifilm Diosynth
  • Novartis
  • Imperial Brands
  • RP (GDP), Cogent Skills gold standard
  • Associate, Chartered Quality Institute
  • BSc (Hons) Biotechnology
  • Lead Auditor trained (IATCA scheme)

We don't just quote the science.
We index it.

A live library of peer reviewed cannabis research, regulatory bulletins and ongoing trials, graded, tagged and updated weekly. Built for clinicians, importers and policy teams who need evidence at hand.

Evidence grading
  • Grade A128
  • Grade B155
  • Grade C154
  • Grade D63
Live, 500 studies indexed
Indexed cannabis research and regulatory bulletins
PubMedEurope PMCClinicalTrials.govNICEMHRAEMA
Grade CRegistered trial2031

Endocannabinoids in Reward

This study aims to investigate sex differences in the effects of cannabis among regular cannabis users. Participants will receive either THC or a placebo, complete questionnaires, undergo a brain scan, and provide a blood sample for genetic testing. The research focuses on understanding the impact of cannabis in individuals with Cannabis Use Disorder.

ClinicalTrials.govn=78
Grade ARCT2030

Warrior CARE: Cannabis Behavioral Health

This is a randomized, controlled clinical trial investigating the therapeutic potential of cannabinoids for treating veterans who suffer from Post Traumatic Stress Disorder (PTSD) and suicidal ideation. The study aims to evaluate the effects of cannabis on mental health conditions in a military veteran population. This trial is currently recruiting participants.

ClinicalTrials.govn=500
Grade CRegistered trial2030

Cannabis Association With Sleep Study

This study investigates the relationship between cannabis use, sleep, and stress levels. It aims to provide insights into how patterns of cannabis consumption correlate with sleep quality and stress in human participants.

ClinicalTrials.govn=60
Open the research library

Latest thinking

Industry7 Sep 2026

UK Medicinal Cannabis: The Unseen Costs of Scale-Up Post-MHRA Review

The UK medicinal cannabis market is maturing, bringing heightened regulatory expectations from the MHRA, particularly regarding operational scale-up. This article explores the unseen financial and operational burdens on licensed producers and distributors as they strive for compliant expansion amidst evolving Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) standards.

Read insight
CBD15 Aug 2026

CBD Isolate Safety: A Clarity Call for UK Novel Food Operators

The recent FSA publication on CBD isolate safety offers a stark reminder of the rigorous standards for novel food approval in the UK. This isn't just about toxicology; it's about the provenance and integrity of every piece of data. Founders and investors must grasp the implications.

Read insight
Investment9 Aug 2026

UK Medicinal Cannabis: Clinical Oversight Tightens for Investor Clarity

A recent focus on robust clinical oversight in medical cannabis therapy, highlighted by international commentary, offers critical insights for the UK market. For founders, boards, and investors, this shift signals a maturing regulatory landscape where patient safety and evidence-based practice are paramount. Understanding these nuances is key to navigating investment opportunities and ensuring long-term operational success in a dynamic sector.

Read insight
Read all insights

Build the UK's most compliant cannabis business, with us.

Or email contact@medicexum.co.uk